BR0213565A - Anticorpo de anti-tnf alfa modificado - Google Patents

Anticorpo de anti-tnf alfa modificado

Info

Publication number
BR0213565A
BR0213565A BR0213565-5A BR0213565A BR0213565A BR 0213565 A BR0213565 A BR 0213565A BR 0213565 A BR0213565 A BR 0213565A BR 0213565 A BR0213565 A BR 0213565A
Authority
BR
Brazil
Prior art keywords
alpha
tnf
modified
tnf antibody
antibody
Prior art date
Application number
BR0213565-5A
Other languages
English (en)
Inventor
Koen Hellendoorn
Matthew Baker
Francis J Carr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0213565A publication Critical patent/BR0213565A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"ANTICORPO DE ANTI-TNF ALFA MODIFICADO". A invenção refere-se a modificação de anticorpos reativos a fator de necrose de tumor humano alfa (TNF-alfa) para resultar em anticorpos de anti-TNF alfa que são substancialmente não imunogênicos ou menos imunogênicos do que qualquer anticorpo de origem não modificado quando usado in vivo. A invenção refere-se também a moléculas de peptídeo compreendendo epítopos de célula T das regiões V do anticorpo de origem que são modificadas por alteração de aminoácido a fim de reduzir ou eliminar os ditos epítopos de célula T.
BR0213565-5A 2001-11-12 2002-11-11 Anticorpo de anti-tnf alfa modificado BR0213565A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126858 2001-11-12
PCT/EP2002/012566 WO2003042247A2 (en) 2001-11-12 2002-11-11 Modified anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
BR0213565A true BR0213565A (pt) 2004-10-26

Family

ID=8179220

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213565-5A BR0213565A (pt) 2001-11-12 2002-11-11 Anticorpo de anti-tnf alfa modificado

Country Status (17)

Country Link
US (2) US7524502B2 (pt)
EP (1) EP1448602B1 (pt)
JP (1) JP4304073B2 (pt)
KR (1) KR20050044405A (pt)
CN (1) CN1585778A (pt)
AT (1) ATE469176T1 (pt)
AU (1) AU2002351957B2 (pt)
BR (1) BR0213565A (pt)
CA (1) CA2466592A1 (pt)
DE (1) DE60236536D1 (pt)
ES (1) ES2346517T3 (pt)
HU (1) HUP0402333A3 (pt)
MX (1) MXPA04004417A (pt)
PL (1) PL369739A1 (pt)
RU (1) RU2004117915A (pt)
WO (1) WO2003042247A2 (pt)
ZA (1) ZA200404626B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009166A1 (en) * 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
EP0981548A4 (en) * 1997-04-30 2005-11-23 Enzon Inc GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
WO2005042581A2 (en) * 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
GB0425713D0 (en) 2004-11-23 2004-12-22 Baker Matthew Immunogencity testing and antibody selection methods
ES2417133T3 (es) 2005-02-03 2013-08-06 Antitope Limited Anticuerpos y proteínas humanas
JP5153613B2 (ja) * 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
EP1904078A4 (en) * 2005-05-12 2009-09-02 Attenuon Llc TREATMENT OF INFLAMMATORY DARMER DISEASES WITH ANTIANGIOGENIC COMPOUNDS
WO2006122787A1 (en) 2005-05-18 2006-11-23 Ablynx Nv Serum albumin binding proteins
EP1919951B1 (en) * 2005-08-04 2015-01-28 Janssen Biotech, Inc. Anti-tnf-alpha antibodies and methods of use
AU2008211227B2 (en) * 2007-01-30 2014-04-17 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
JP2010530895A (ja) 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CN102597775A (zh) 2009-09-25 2012-07-18 佐马技术有限公司 筛选方法
NZ621655A (en) 2009-10-26 2015-08-28 Nestec Sa Assays for the detection of anti-tnf drugs and autoantibodies
JP5767708B2 (ja) * 2010-09-30 2015-08-19 ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド ヒト化抗ヒト腫瘍壊死因子α（ＴＮＦ−α）抗体およびその抗原結合性フラグメント（Ｆａｂ）およびその使用方法
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CN103501815B (zh) 2010-10-08 2016-09-28 希望之城公司 针对中间位的单克隆抗体框架结合界面、中间位投递系统及其使用方法
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
US8658171B2 (en) 2011-02-28 2014-02-25 Livzon Mabpharm Inc. Humanized anti-TNFα antibodies
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
MX343324B (es) 2011-07-06 2016-11-01 Nestec Sa Ensayos para detectar auto anticuerpos neutralizadores de la terapia biologica con tnf alpha.
US9428553B2 (en) 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
WO2014193973A2 (en) 2013-05-28 2014-12-04 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
RU2556816C1 (ru) * 2014-03-12 2015-07-20 Открытое акционерное общество "Фармацевтический импорт, экспорт" (ОАО "Фармимэкс") Штамм клеток яичников китайского хомячка - продуцент рекомбинантного антитела против фактора некроза опухоли альфа человека
WO2016088104A2 (en) 2014-12-05 2016-06-09 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
CN105820246A (zh) * 2015-01-07 2016-08-03 上海张江生物技术有限公司 一种新型重组抗TNFα嵌合单克隆抗体制备方法及用途
WO2016153838A1 (en) * 2015-03-20 2016-09-29 Full Spectrum Genetics, Inc. Novel anti-tnfa binding compounds and uses thereof
MY194619A (en) 2016-06-02 2022-12-07 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
CA3058156C (en) 2017-03-30 2025-05-06 Blonder Tongue Laboratories, Inc. ENTERPRISE CONTENT GATEWAY
AU2018374634A1 (en) 2017-12-01 2020-05-28 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2020206149A2 (en) * 2019-04-05 2020-10-08 The Regents Of The University Of California Methods and compositions involving chimeric binding polypeptides
CN111909267B (zh) * 2019-05-07 2022-03-25 北京天成新脉生物技术有限公司 低免疫原性抗TNF-α人源化单克隆抗体TCX063及其应用
GB202004916D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Antibodies
KR20230112629A (ko) * 2020-10-23 2023-07-27 에이치큐 한 종양괴사인자-알파 및 형질전환성장인자-베타의 이작용성 길항제 및 이의 용도
GB2644591A (en) * 2023-06-08 2026-04-15 Xentria Inc Methods for detecting a neutralizing antibody (NAB) against an anti-TNF alpha antibody

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1097945B1 (en) * 1991-03-18 2007-07-04 New York University Monoclonal and chimeric antibody specific for human tumor necrosis factor
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US5519000A (en) * 1994-04-01 1996-05-21 Centecor, Inc. Tumor necrosis factor inhibitors
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
WO2000034317A2 (en) * 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
EP1230269A2 (en) * 1999-11-03 2002-08-14 Maxygen, Inc. Antibody diversity generation
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
MXPA03007316A (es) * 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.

Also Published As

Publication number Publication date
US20060018903A1 (en) 2006-01-26
RU2004117915A (ru) 2005-05-10
HUP0402333A3 (en) 2007-05-02
WO2003042247A2 (en) 2003-05-22
US20040260069A1 (en) 2004-12-23
WO2003042247A3 (en) 2004-03-11
JP4304073B2 (ja) 2009-07-29
AU2002351957B2 (en) 2009-09-03
EP1448602B1 (en) 2010-05-26
ZA200404626B (en) 2005-10-26
DE60236536D1 (de) 2010-07-08
US7754853B2 (en) 2010-07-13
CN1585778A (zh) 2005-02-23
KR20050044405A (ko) 2005-05-12
MXPA04004417A (es) 2004-08-11
ATE469176T1 (de) 2010-06-15
US7524502B2 (en) 2009-04-28
PL369739A1 (en) 2005-05-02
ES2346517T3 (es) 2010-10-18
CA2466592A1 (en) 2003-05-22
HUP0402333A2 (hu) 2005-02-28
EP1448602A2 (en) 2004-08-25
JP2005510216A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
PL378333A1 (pl) Sposoby profilaktyki i leczenia choroby Alzheimera (AD)
MXPA04008077A (es) Anticuerpos ant-a° y su uso.
JP2006526414A5 (pt)
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
MX2012005864A (es) Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
BRPI0418766A (pt) anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1
BR0209177A (pt) Anticorpo especìfico a tumor recombinante e uso do mesmo
DE602005016712D1 (de) Rter dna
NO995002D0 (no) Modifiserte TNF-<alfa>-molekyler, DNA som koder for slike modifiserte TNF-<alfa>-molekyler og vaksiner omfattende slike TNF-<alfa>-molekyler og DNA
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
BRPI0513798A (pt) anticorpos anti-cd154
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
BR0308860A (pt) Fator viii modificado
WO2007018619A3 (en) Chimeric therapeutic agents
BRPI0500311A (pt) processo de preparação de uma composição de tratamento cosmético das matérias queratìnicas, composição de tratamento cosmético das matérias queratìnicas, processos de tratamento cosmético das matérias queratìnicas, dispositivo de condicionamento de uma composição cosmética e uso de uma composição
ATE509025T1 (de) ßMIT MHC-KLASSE-I-PEPTIDEPITOPEN KOVALENT VERKN PFTES MEMBRANVERANKERTES BETA2-MIKROGLOBULINß
ATE360642T1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
CN100402551C (zh) β2-微球蛋白的抗原表位及应用
BR0311308A (pt) Briodina 1 modificada com imunogenicidade reduzida
CN114805584A8 (zh) 抗原结合蛋白及其用途
DK1913020T3 (da) Immunogene konstrukter
WO2008029138A3 (en) Peptides and methods
BR0214567A (pt) Epìtopos de célula t em carboxipeptidase g2

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A., 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.